Medipharm Labs Corp T.LABS

No miracles needed.

[alleyesonme]

"This business continues to develop with the approach of FDA patent challenges for current forms of generic drugs""...plus first advanced CBD isolate deliveries to traditional pharma...this is no LP...they have the DEL and now the pharmaceutical doors are open...50m market cap....are you fackn kidding...so many have been burned however 2022 is going to be a really big " comeback year".....heavy lifting is done...new leadership was needed...my top pick for the new year.

[anjz661]

Agreed, the heavy lifting is done.  They are in a good place right now and 2022 could have a favourable outcome. I strongly suspect they aready have a plan to deploy that cash to increase profitability as well.

[allibabba]

To your point mdjbrown, 80% of CBD companies are in dire straits.  Only two or three will survive.  The undertaker will be busy in 2022 with MJ companies.

[mdjbrown]

Agree 100% allibabba 2022 will be a year that weeds the contenders from the pretenders, and my guess is the carefully layed foundation by Medipharm in 2020 / 2021 lead by new vision will be enough to attach a contender tag on it A stock beaten up so bad despite promising results, usually goes in one direction as it recovers and with tax loss selling over and the number of shorts still out, it

[allibabba]

Agreed.  GO LABS ffs.  

[alleyesonme]

The new big pharmaceutical companies will continue placing orders...International sales will continue growing as regulatory hurdles continue to be completed....why would the CFO and only the CFO get such a generous reward at the end of Q4????it's not because he's doing a shitty job... next financials will be solid no question. When will they announce they've released generic version of

[anjz661]

I always think of this at the retail level, when a neighborhood gets complaints that there are too many MJ stores in a particular neighborhood, give it a year or two, they won't all survive.

[mdjbrown]

Agree anjz661 Over saturation in any market often leads to the demise of some of the players involved, often due to high debt / little revenue. Luckily, at the moment Medipharm appears to have very little debt, and a fist full of cash to ride out the turbulence as they build their brand throw trials and international growth. Millions more available if they can create a .70 cent or higher

[gossamer3]

This post has been removed in accordance with Community Policy